Registration statement

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm - KVUE

Retrieved on: 
Friday, October 27, 2023
Titan, Register, NYSE, KVUE, Registration statement, Court, I-Space (Chinese company), Advertising, Phenylephrine, Prospectus, Plaintiff, Insurance, Tobacco, IPO

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, October 26, 2023
Capital market, Sale, Register, The Women on the 6th Floor, Toronto Stock Exchange, EDGAR, Registration statement, Form, News, Option, Private, Attention, Investissement Québec, Indian stock exchange, Public, Marathon Asset Management, TSX, Security (finance)

MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”). The gross proceeds of the Public Offering are expected to be approximately US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriter a 30-day option (the “Option”) to purchase up to 1,875,000 Common Shares at the Offering Price, less underwriting discounts and commissions.

Key Points: 
  • MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”).
  • The gross proceeds of the Public Offering are expected to be approximately US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses.
  • In connection with the Public Offering, the Company entered into a subscription agreement with Investissement Québec for a concurrent private placement (the “Concurrent Private Placement”) of 9,118,184 Common Shares and 3,381,816 fully-funded, non-voting subscription receipts, exchangeable into Common Shares on a one-for-one basis (the “Exchangeable Subscription Receipts”) in lieu of Common Shares, in each case, at the Offering Price, for US$12,500,000 aggregate gross proceeds, less a capital commitment fee of 1.5% payable to Investissement Québec.
  • The closing of the Public Offering and the Concurrent Private Placement are conditional upon each other.

DIRTT files a S-1 Registration Statement with the SEC

Retrieved on: 
Thursday, October 26, 2023
Registration statement, Sale, Register, Form, Rights, TSX, Indian stock exchange, Investment, DRT, Security (finance)

CALGARY, Alberta, Oct. 26, 2023 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT; OTC: DRTTF), a leader in industrialized construction, announced today that it has filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the "SEC") for a potential rights offering at a future date, pursuant to which the Company may distribute at its sole discretion, at no charge, to holders of the Company's common shares transferable rights to purchase additional common shares of the Company.

Key Points: 
  • CALGARY, Alberta, Oct. 26, 2023 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT; OTC: DRTTF), a leader in industrialized construction, announced today that it has filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the "SEC") for a potential rights offering at a future date, pursuant to which the Company may distribute at its sole discretion, at no charge, to holders of the Company's common shares transferable rights to purchase additional common shares of the Company.
  • The Company has not made any determination to proceed with a rights offering and no record date has been set in respect of any rights offering.
  • The Registration Statement relating to the proposed rights offering has been filed with the SEC but has not yet become effective.
  • The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

GIGACLOUD ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GigaCloud Technology Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 26, 2023
Research, IPO, Register, Complaint, GCT, Report, Person, Telephone, Registration statement, News, Court, P.C, Prospectus, District court, Central District, Defendant, Security (finance)

Investors have until December 4, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 4, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • In August 2022, GigaCloud conducted its IPO, selling 3,381,000 Class A ordinary shares at $12.25 per share, receiving net proceeds of approximately $34.2 million.
  • On September 28, 2023, before the market opened, Culper Research published a report alleging “numerous glaring flaws” in GigaCloud’s public reporting.

KENVUE INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Kenvue Inc. (NYSE: KVUE)

Retrieved on: 
Wednesday, October 25, 2023
IPO, Register, NYSE, Food, KVUE, Registration statement, Court, Disclosure, Complaint, Phenylephrine, Prospectus, District court, Advertising, Food and Drug Administration, Security (finance)

If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.

Key Points: 
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] .
  • If you purchased or acquired Kenvue securities, and/or would like to discuss your legal rights and options please visit Kenvue Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Wednesday, October 25, 2023
Capital market, Sale, Register, The Women on the 6th Floor, Toronto Stock Exchange, EDGAR, Registration statement, News, Private, Attention, Public offering, Indian stock exchange, Public, TSX, Security (finance)

MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “Public Offering”) of common shares of the Company (the “Common Shares”). The Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of Common Shares to be sold pursuant to the Public Offering (the “Option”).

Key Points: 
  • MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “Public Offering”) of common shares of the Company (the “Common Shares”).
  • In connection with the Public Offering, the Company intends to enter into a subscription agreement with Investissement Québec for a concurrent private placement of Common Shares (and Common Share equivalents in the form of pre-funded, non-voting subscription receipts, exchangeable into Common Shares on a one-for-one basis (the “Exchangeable Subscription Receipts”) in lieu of Common Shares), for up to US$12.5 million aggregate gross proceeds (the “Concurrent Private Placement”).
  • The consummation of the Concurrent Private Placement will be contingent upon the closing of the Public Offering.
  • Completion of the Public Offering and Concurrent Private Placement will be subject to customary closing conditions, including the listing of the Common Shares and the Common Shares underlying the Exchangeable Subscription Receipts on the Toronto Stock Exchange and the submission of notice to the Nasdaq Global Market.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Wednesday, October 25, 2023
Suite, FDA, Nasal, Register, NYSE, KVUE, Registration statement, News, Court, PE, Phenylephrine, Prospectus, GPM, Nasal congestion, Risk, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry, IPO

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

KVUE SHAREHOLDERS: Contact Robbins LLP if You Have Incurred Substantial Losses in Kenvue Inc.

Retrieved on: 
Tuesday, October 24, 2023
FDA, Nasal, Register, NYSE, Food, KVUE, Person, Registration statement, PE, LLP, Phenylephrine, Prospectus, Risk, Nasal congestion, SAN, Criticism of the Food and Drug Administration, Security (finance), Pharmaceutical industry, IPO

Kenvue Inc. operates as a consumer health company worldwide.

Key Points: 
  • Kenvue Inc. operates as a consumer health company worldwide.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

DevvStream Reaches Key Milestone Toward Nasdaq Listing

Retrieved on: 
Tuesday, October 24, 2023
Combination, Register, Public Company Accounting Oversight Board, Security (finance), Business analyst, Form, Carbon, Transaction, Bank statement, Registration statement, FIAC, CBOE, FSE, DESG, Culture

The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.

Key Points: 
  • The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.
  • The Business Combination is expected to be completed by early Q1 2024, subject to the satisfaction of closing conditions under the Business Combination Agreement.
  • Learn more about the Company’s progress by joining a live webinar presented by DevvStream and Focus Impact on Thursday, October 26th at 9:30am PT / 12:30pm ET.
  • “Since DevvStream and Focus Impact agreed to merge, the transaction has proceeded smoothly and efficiently,” said Sunny Trinh, CEO of DevvStream.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GigaCloud Technology Inc. (GCT)

Retrieved on: 
Monday, October 23, 2023
Suite, Research, IPO, Complaint, Register, GCT, Report, Registration statement, News, Court, Prospectus, GPM, Defendant, Security (finance)

In August 2022, GigaCloud conducted its IPO, selling 3,381,000 Class A ordinary shares at $12.25 per share, receiving net proceeds of approximately $34.2 million.

Key Points: 
  • In August 2022, GigaCloud conducted its IPO, selling 3,381,000 Class A ordinary shares at $12.25 per share, receiving net proceeds of approximately $34.2 million.
  • On September 28, 2023, before the market opened, Culper Research published a report alleging “numerous glaring flaws” in GigaCloud’s public reporting.
  • If you purchased or otherwise acquired GigaCloud securities, you may move the Court no later than December 4, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.